<SEC-DOCUMENT>0000950170-23-070211-index.html : 20231214
<SEC-HEADER>0000950170-23-070211.hdr.sgml : 20231214
<ACCEPTANCE-DATETIME>20231214074354
ACCESSION NUMBER:		0000950170-23-070211
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20231214
FILED AS OF DATE:		20231214
DATE AS OF CHANGE:		20231214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Virax Biolabs Group Ltd
		CENTRAL INDEX KEY:			0001885827
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41440
		FILM NUMBER:		231485570

	BUSINESS ADDRESS:	
		STREET 1:		30 BROADWICK STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1F 8LX
		BUSINESS PHONE:		44 020 7788 7414

	MAIL ADDRESS:	
		STREET 1:		30 BROADWICK STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1F 8LX

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Virax Biolabs (Cayman) Ltd
		DATE OF NAME CHANGE:	20210930
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>6-k_press_release_share_.htm
<DESCRIPTION>6-K
<TEXT>
Document 1 - file: 6-k_press_release_share_.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vrax-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: vrax-ex99_1.htm

</DOCUMENT>
</SEC-DOCUMENT>